Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation | |
|---|---|---|
| D024821 | Metabolic Syndrome NIH | 0.45 |
| D013577 | Syndrome NIH | 0.09 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Specific Aim #1 (Feasibility; primary aim): To assess the feasibility of the PP-MI group-based physical activity intervention and outcome assessments in patients with MetS. Hypothesis: The PP exercises and MI-based goal-setting sessions will be feasible: most (≥50%) of participants will complete 6/9 exercises/sessions. Furthermore, the investigators will be able to obtain objective physical activity measurement follow-up data from at least 80% of enrolled participants at the end of the intervention and 24 weeks later. Specific Aim #2 (Acceptability): To assess whether the intervention is acceptable to participants, as measured by ratings provided after each PP-MI session. Hypothesis: The intervention will be acceptable: participants will rate the PP-MI exercises with a mean score of at least 7 out of 10 on ease of completion and helpfulness. Specific Aim #3 (Outcomes): To assess whether this preliminary intervention appears to result in improvement of physical activity, related health behaviors (sedentary time, diet quality), psychological well-being (optimism, positive affect, anxiety, depression), and the exploratory outcomes of MetS-relevant physiological markers (e.g., blood pressure, weight, chart-reviewed lipids and HbA1C). Hypothesis a: The intervention will lead to improvements in physical activity, related health behaviors, optimism and positive affect, reductions in depression and anxiety at 9 weeks and 24 weeks compared to baseline (or the start of the intervention, for the WLC group). Hypothesis b: The hypothesis is that there will be improvements in the exploratory outcomes of the physiological markers, even if they do not reach significance.
Description: Feasibility will be measured by examining the number of completed exercises.
Measure: Feasibility of the PP-MI-Based Health Behavior Intervention Time: 8 weeks of group sessionsDescription: Participants will rate the ease and usefulness of each weekly activity (0-10).
Measure: Acceptability of Intervention Time: 8 weeksDescription: ActiGraph GT3X+ accelerometers are validated as measures of physical activity and have been used in numerous studies of physical activity in patients with medical illness. In this trial, participants will wear the accelerometer to assess the feasibility of doing so and to ensure adequate capture of physical activity.
Measure: Physical Activity Adherence (Actigraph) Time: Baseline, weeks 9, 24 (baseline, weeks 9, 17, 33 for the WLC group)Description: Feasibility will be measured by examining the rates of use of the Actigraph.
Measure: Feasibility of Actigraph Time: Baseline, weeks 9, 24 (baseline, weeks 9, 17, 33 for the WLC group)Description: The LOT-R is a well-validated 6-item instrument used to measure dispositional optimism. (Range: 5-30)
Measure: Changes in Life Orientation Test- Revised Scores Time: Baseline, weeks 9, 24 (Baseline, weeks 17 and 33 for the WLC group)Description: The positive affect items on the Positive and Negative Affect Schedule (PANAS), a well-validated scale used in other intervention trials, will be used to measure positive affect. (Range: 10-50)
Measure: Changes in Positive and Negative Affect Schedule Scores Time: Baseline, weeks 9, 24 (Baseline, weeks 17 and 33 for the WLC group)Description: The HADS will be used to measure depression and anxiety. This is a well-validated scale with few somatic symptom items that can confound mood/anxiety assessment in medically-ill patients. (Range: HADS-A, HADS-D; 0-21 each)
Measure: Changes in The Hospital Anxiety and Depression Scale Scores Time: Baseline, weeks 9, 24 (Baseline, weeks 17 and 33 for the WLC group)Description: The BBAQ is a 21-item measure, published by the US Centers for Disease Control and Prevention (CDC), that explores seven main categories of barriers, including lack of time, energy, and resources. (Range: 0-63)
Measure: Changes in Barriers to Being Active Quiz Scores Time: Baseline, weeks 9, 24 (Baseline, weeks 17 and 33 for the WLC group)Description: The SOM will be used to capture the changeable nature of optimism based on time and situation. (Range: 7-35)
Measure: Changes in State Optimism Measure Time: Baseline, weeks 9, 24 (Baseline, weeks 17 and 33 for the WLC group)Description: The SF-12 will be used to measure quality of life. This instrument has been used in many patient-oriented studies. (Range: SF-12 PCS and SF-12 MCS); range 0-100 each)
Measure: Changes in The Medical Outcomes Study Short Form-12 Scores Time: Baseline, weeks 9, 24 (Baseline, weeks 17 and 33 for the WLC group)Description: The IPAQ-SF is a validated scale that measures self-reported physical activity in the past 7 days in the domains of vigorous activity, moderate activity, and walking.
Measure: Changes in The International Physical Activity Questionnaire-Short Form Scores Time: Pre-baseline screening, weeks 9, 24 (Pre-baseline, weeks 17 and 33 for the WLC group)Description: The CDC's BRFSS Fruit and Vegetable Module is a brief questionnaire about frequency of eating different types of fruits and vegetables.
Measure: Changes in Behavioral Risk Factor Surveillance System Fruit and Vegetable Module Time: Baseline, weeks 9, 24 (Baseline, weeks 17 and 33 for the WLC group)Description: The National Cancer Institute's Percentage Energy from Fat Screen is a brief questionnaire that estimates people's typical percentage of energy derived from eating common fat-containing foods, as fat content is related to metabolic syndrome progression.
Measure: Changes in National Cancer Institute's Percentage Energy from Fat Screener Scores Time: Baseline, weeks 9, 24 (Baseline, weeks 17 and 33 for the WLC group)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports